Full-Time

QC Inspector 1

Confirmed live in the last 24 hours

Dexcom

Dexcom

5,001-10,000 employees

Develops continuous glucose monitoring systems

Compensation Overview

$16.58 - $27.64/hr

Entry, Junior

Company Does Not Provide H1B Sponsorship

Mesa, AZ, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • Understand basic visual and dimensional inspection techniques
  • Ability to follow written procedures and take direction from supervisor and/or other designated personnel in execution of QC inspection assignments
  • Demonstrate basic computer skills and perform basic computer transactions
  • Exhibit good organizational skills and attention to detail
  • Have good written and verbal communication skills
  • Can work flexible hours, including possible rotating schedules that may include early morning or evening hours, holidays, and weekends
Responsibilities
  • Responsible for visual and/or dimensional QC inspection and/or testing of incoming quarantined materials, inspection of in-process materials, labeling, and final commercial product
  • Responsible for quarantine storage of materials and accurate inventory transactions within the MRP system
  • Accurately recording inspection results and maintaining good documentation practices
  • Utilize basic computer skills to perform computer transactions related to inspection activities
  • Assume and perform other duties as assigned
Desired Qualifications
  • Experience using vision systems to measure medical device components

Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides users with real-time glucose readings, enabling better control of their condition. The system includes a sensor that is placed under the skin, which continuously measures glucose levels and sends the data to a smartphone app or receiver. This allows users to track their glucose levels throughout the day without the need for fingerstick tests. Dexcom differentiates itself from competitors by offering a user-friendly interface and advanced data analytics through its Dexcom CLARITY software, which helps users and healthcare providers make informed decisions based on glucose trends. The company's goal is to enhance the quality of life for people with diabetes by providing accurate and accessible glucose monitoring solutions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance of G7 system enhances Dexcom's market credibility.
  • Integration with telehealth services boosts patient engagement and adherence.
  • AI integration in CGM systems improves predictive analytics and patient outcomes.

What critics are saying

  • Competition from Abbott's FreeStyle Libre 3 may impact market share.
  • Data privacy concerns with third-party platform integrations could deter users.
  • Hiring 1000 skilled workers may strain resources and cause inefficiencies.

What makes Dexcom unique

  • Dexcom G7 offers a 15-day wear period, reducing sensor replacements.
  • Direct Apple Watch connectivity allows glucose monitoring without an iPhone.
  • Dexcom CLARITY app provides detailed glucose patterns and trends analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Our Health Needs
Apr 14th, 2025
Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

In March, cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with Dexcom to integrate glucose data from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable.

Hit Consultant
Apr 10th, 2025
Fda Clears Dexcom G7 15 Day Continuous Glucose Monitoring System

What You Should Know:– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.– The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.Dexcom G7 FeaturesThe Dexcom G7 15 Day system offers up to 15.5 days of wear allowing users to benefit from fewer monthly sensors and reduced monthly waste. The waterproof CGM system provides an overall MARD of 8.0%.Other key features of Dexcom G7 include:Apple Watch Connectivity: Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone.Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone. Automated Logging: Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels.Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels. 12-Hour Grace Period: A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions.A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions. Mobile App with Dexcom Clarity: An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports.An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports

wflqzhanghaoran
Mar 27th, 2025
Dexcom COO on 15-day glucose sensor, Type 2 coverage | MedTech Dive

Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference.

MPO Magazine
Mar 26th, 2025
Dexcom Names Masimo Exec Jon Coleman as CCO

Dexcom names Masimo exec Jon Coleman as CCO.

Galway Beo
Mar 22nd, 2025
Dexcom opening date hiring 1000 jobs as highly skilled workers wanted

Dexcom opening date hiring 1000 jobs as highly skilled workers wanted.